Optimization of benzothiazole and thiazole hydrazones as inhibitors of schistosome bcl-2a (Publications)
Limited therapeutic options are available for the treatment of human schistosomiasis caused by the parasitic Schistosoma flatworm. The B cell lymphoma-2 (BCL-2)-regulated apoptotic cell death pathway
Quest for a potent antimalarial drug lead: synthesis and evaluation of 6,7-dimethoxyquinazoline-2,4-diamines (Publications)
Quinazolines have long been known to exert varied pharmacologic activities that make them suitable for use in treating hypertension, viral infections, tumors, and malaria. Since 2014, we have synthesi
Parasite-host dynamics throughout antimalarial drug development stages complicate the translation of parasite clearance (Publications)
Ensuring continued success against malaria depends on a pipeline of new antimalarials. Antimalarial drug development utilizes pre-clinical murine and experimental human malaria infection studies to ev
Investigation of heterochromatin protein 1 function in the malaria parasite <em>Plasmodium falciparum</em> using a conditional domain deletion and... (Publications)
The human malaria parasite Plasmodium falciparum encodes a single ortholog of heterochromatin protein 1 (PfHP1) that plays a crucial role in the epigenetic regulation of various survival-related proce
Poverty is not poverty: the reality on the ground including the rural-urban divide and how we can turn the tide on NCDs (Publications)
Cardiovascular diseases (CVDs) tend to occur in younger sub-Saharan African (SSA) populations, about 20 years earlier as compared to high income countries (HIC). Weak health systems and infrastructure
Development and validation of an LC-MS/MS method for the quantification of the anthelmintic drug moxidectin in a volumetric absorptive microsample,... (Publications)
Moxidectin is a promising candidate for addition to the lean repertoire of drugs against neglected tropical diseases (NTD) including strongyloidiasis. Pharmacokinetic (PK) and -dynamic studies are req